Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women

Gambacciani, Marco; Cappagli, Barbara; Ciaponi, Massimo; Pepe, Angeliki-Eirini; Vacca, Francesca; Genazzani, Andrea Riccardo

doi:10.1016/j.maturitas.2007.10.007

Cited by 42 publications

(26 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In an open trial healthy postmenopausal women received for 2 years a low-dose continuous combined HRT containing 1mg estradiol plus 0.5 mg norethisterone acetate, or 0.5 mg of 17-estradiol and 0.25 mg of norethisterone acetate (ultra low dose) along with 1000 mg of calcium per day. The study confirmed that low-dose-HRT and Ultra-low-dose-HRT can alleviate subjective symptoms providing an effective protection against the postmenopausal decrease of BMD (Gambacciani et al, 2008).…”

Section: Hrt -Type Dosesupporting

confidence: 65%

The Role of Hormone Replacement Therapy (HRT) and Tibolone in the Prevention and Treatment of Postmenopausal Osteoporosis

Lamarca¹

2012

Osteoporosis

View full text Add to dashboard Cite

Section: Hrt -Type Dosesupporting

confidence: 65%

The Role of Hormone Replacement Therapy (HRT) and Tibolone in the Prevention and Treatment of Postmenopausal Osteoporosis

Lamarca¹

2012

Osteoporosis

View full text Add to dashboard Cite

“…More recent studies show that even low doses of HRT may protect bone by decreasing BTM levels (Bone turnover marker) and preventing bone loss 37,38 . The anti-fracture efficacy of these regimens has not been studied.…”

Section: Hormone Replacement Therapy (Hrt)mentioning

confidence: 99%

Untitled

2017

IJPSR

View full text Add to dashboard Cite

ABSTRACT:The aim of this review is to assess the efficacy of treatments for postmenopausal osteoporosis in women with low bone mass or with an existing vertebral fracture. Osteoporosis is a worldwide health problem related to the aging of the population, and it is often under diagnosed and undertreated. It is related to substantial morbidity, mortality and impairment of the quality of life. Estrogen deficiency is the major contributing factor to bone loss after menopause. Postmenopausal osteoporosis is a silent disease in most cases, with no symptoms until fractures occur. It is characterized by low bone mineral density (BMD) and changes in bone micro architecture that reduce bone strength and increase fracture risk. The objective of this study was to present a systematic review of drugs for treatment of osteoporosis, focusing on the adequacy of clinical protocols based on existing evidence in the scientific literature. So, our study recommends that postmenopausal women should be screened for osteoporotic fracture risk which may be important strategy in the management of postmenopausal osteoporosis.

show abstract

“…В многогранной пробле-ме климактерического синдрома имеется довольно много спорных или пока еще не получивших адек-ватного решения вопросов [1,2,23].…”

Section: заключениеunclassified

The use of lowest doses of menopausal hormone therapy

Yureneva¹,

Dubrovina²

2015

Probl. reprod.

View full text Add to dashboard Cite

Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women

Cited by 42 publications

References 34 publications

The Role of Hormone Replacement Therapy (HRT) and Tibolone in the Prevention and Treatment of Postmenopausal Osteoporosis

The Role of Hormone Replacement Therapy (HRT) and Tibolone in the Prevention and Treatment of Postmenopausal Osteoporosis

Untitled

The use of lowest doses of menopausal hormone therapy

Contact Info

Product

Resources

About